Home
Issues
Aim and Scope
Open Access
Editorial Board
Indexing
Why publish with us
Contact Us
Instructions to Authors (PDF)
Manuscript Types
Manuscript Formatting
How to submit
Preprints
Special publications & Reprints
Authorship & COI
Principles of Transparency Checklist
Data Policies
Publication Ethics and Publication Malpractice Statement
Crossmark
Supporting Diversity
Protocol of a longitudinal population-based study evaluating the impacts of the COVID-19 pandemic on children and adolescents: the SEROCoV-KIDS cohort and biobank
1
Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland
2
Division of General Pediatrics, Department of Woman, Child, and Adolescent Medicine, Geneva University Hospitals, Geneva, Switzerland
3
Division of Child and Adolescent Psychiatry, Department of Woman, Child, and Adolescent Medicine, Geneva University Hospitals, Geneva, Switzerland
4
Division and Department of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland; Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland
Publication date: 2023-04-26
Popul. Med. 2023;5(Supplement):A1107
ABSTRACT
Background and Objective:
Recent observational research has revealed the impacts of the COVID-19 pandemic on the multiple dimensions of children’s life coming from diverse socioeconomic backgrounds. Determining the consequences of the pandemic on this population over the longer term is a public health priority.
Methods:
SEROCoV-KIDS is an on-going, 3-year longitudinal and prospective cohort study to monitor and determine the direct and indirect impacts of the COVID-19 pandemic on the health and development of children (aged 6 months to 17 years) living in Geneva, Switzerland. The study integrates a paediatric biobank and a research collaborative network. Its cohort is composed of a general population-based sample (targeted N, 2000) and a sample of children with social or clinical vulnerabilities (targeted N, 500). Participants are enrolled during the first 12 months of the 30-month data collection phase. Individual consent is provided by the referent adult and adolescent, aged 14 years or older. Participation includes a baseline serological blood test, and online questionnaires at the baseline assessment and every 4 months thereafter. The outcomes are general and mental health, development trajectory, education, family socioeconomic environment, lifestyle, health behaviors, healthcare consumption, and COVID-19 exposure.
Results:
The study began on September, 2021 and will be completed in August 2024. As of November 2022, 2145 children are being followed up. A total of 1829 serologies (85%) were performed and most participants (83%) agreed to the biobank. The inclusion questionnaires were completed by 1750/2145 referent adults (96%) and 423/480 adolescents (88%).
Conclusions:
SEROCoV-KIDS is a uniquely large cohort study monitoring the health and development of children of all ages over time, and an opportunity to build a biobank for future translational research. Its findings will provide an evidence base to guide public policies and future programs for the young population, particularly for those in vulnerable situations.
Recent observational research has revealed the impacts of the COVID-19 pandemic on the multiple dimensions of children’s life coming from diverse socioeconomic backgrounds. Determining the consequences of the pandemic on this population over the longer term is a public health priority.
Methods:
SEROCoV-KIDS is an on-going, 3-year longitudinal and prospective cohort study to monitor and determine the direct and indirect impacts of the COVID-19 pandemic on the health and development of children (aged 6 months to 17 years) living in Geneva, Switzerland. The study integrates a paediatric biobank and a research collaborative network. Its cohort is composed of a general population-based sample (targeted N, 2000) and a sample of children with social or clinical vulnerabilities (targeted N, 500). Participants are enrolled during the first 12 months of the 30-month data collection phase. Individual consent is provided by the referent adult and adolescent, aged 14 years or older. Participation includes a baseline serological blood test, and online questionnaires at the baseline assessment and every 4 months thereafter. The outcomes are general and mental health, development trajectory, education, family socioeconomic environment, lifestyle, health behaviors, healthcare consumption, and COVID-19 exposure.
Results:
The study began on September, 2021 and will be completed in August 2024. As of November 2022, 2145 children are being followed up. A total of 1829 serologies (85%) were performed and most participants (83%) agreed to the biobank. The inclusion questionnaires were completed by 1750/2145 referent adults (96%) and 423/480 adolescents (88%).
Conclusions:
SEROCoV-KIDS is a uniquely large cohort study monitoring the health and development of children of all ages over time, and an opportunity to build a biobank for future translational research. Its findings will provide an evidence base to guide public policies and future programs for the young population, particularly for those in vulnerable situations.
| ISSN: | 2654-1459 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
